Skip to main content

Market Overview

Jefferies Likes Hologic For Zika, But Sees Blood Screening As Larger Opportunity

Share:
Jefferies Likes Hologic For Zika, But Sees Blood Screening As Larger Opportunity

Hologic, Inc. (NASDAQ: HOLX) shares outperformed very modestly Monday following news the company and Grifols' Zika virus assay received FDA approval. The stock closed up nearly 1 percent versus a 0.73 percent rally in the Dow Jones Industrial Average and a 0.58 percent increase in the S&P 500 cash.

Jefferies' Raj Denhoy offered his thoughts amid the news.

"While positive, the financial impact of the approval should be minimal. Hologic’s test is the fourth now available and the use case for individual testing is still very limited. Authorization for Zika testing in blood screening is expected any day and that test has the potential to be more meaningful," according to Denhoy.

The Jefferies analyst gave detail into that "more meaningful" opportunity. Denhoy noted if active screening is adopted, Hologic's opportunity could be in the $20 million to $25 million per year range.

Jefferies and Denhoy maintained a Buy rating and $42 price target on shares of Hologic.

Latest Ratings for HOLX

DateFirmActionFromTo
Apr 2021JefferiesMaintainsBuy
Feb 2021BairdMaintainsBuy
Dec 2020Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings

 

Related Articles (HOLX)

View Comments and Join the Discussion!

Posted-In: Jefferies Raj Denhoy ZikaAnalyst Color News Analyst Ratings

Latest Ratings

StockFirmActionPT
GDWolfe ResearchDowngrades
QRTEAB of A SecuritiesInitiates Coverage On
ABB of A SecuritiesDowngrades42.0
VCTRB of A SecuritiesUpgrades32.0
BSIGB of A SecuritiesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com